{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:23:40Z","timestamp":1777965820750,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Survival rates of patients with non\u2010Hodgkin lymphoma (NHL) have improved over the last decade. However, cardiotoxicities remain important adverse consequences of treatment with chemotherapy and radiation, although the burden of cardiovascular mortality (CVM) in such patients remains unknown. We conducted a retrospective cohort study of patients greater than or equal to 20\u00a0years of age diagnosed with diffuse large B\u2010cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) between 2000 and 2013 using data extracted from the United States Surveillance, Epidemiology, and End Results (SEER) database. Our primary endpoint was CVM. The association between NHL and CVM was evaluated using multivariable Cox regression analysis after adjusting for other patient characteristics. We calculated standardized mortality ratios (SMRs) for CVM, comparing NHL patients with the general population. We identified 153\u00a0983 patients who met the inclusion criteria (69\u00a0329 with DLBCL, 48\u00a0650 with CLL\/SLL, and 36\u00a0004 with FL). The median follow\u2010up was 37\u00a0months (interquartile range, 10\u201078\u00a0months); the mean patient age was 66.24 (\u00b114.69) years; 84\u00a0924 (55.2%) were men; 134\u00a0720 (87.5%) were White, and 131\u00a0912 (85.7%) did not receive radiation therapy. Overall, 9017 patients (5.8%) died from cardiovascular disease, and we found that NHL patients had a higher risk of CVM than the general population, after adjusting for age (SMR 15.2, 95% confidence interval: 14.89\u201015.52). The rates of CVM were 5.1%, 8%, and 4.4% in patients with DLBCL, CLL\/SLL, and FL, respectively. Furthermore, across all NHL subtypes, older age, higher stage at the time of diagnosis (particularly stage 4), male sex, and living in the south were associated with higher risks of CVM. Our data suggest that risk assessment and careful cardiac monitoring are recommended for NHL patients, particularly those with the CLL\/SLL subtypes.<\/jats:p>","DOI":"10.1002\/hon.2607","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T23:54:46Z","timestamp":1553730886000},"page":"261-269","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cardiovascular mortality among patients with non\u2010Hodgkin lymphoma: Differences according to lymphoma subtype"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-2384","authenticated-orcid":false,"given":"Hasan","family":"Abuamsha","sequence":"first","affiliation":[{"name":"Department of Medicine St. Vincent Charity Medical Center \u2013 Case Western Reserve University  Cleveland Ohio United States of America"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-3389","authenticated-orcid":false,"given":"Amer N.","family":"Kadri","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Medicine Institute Cleveland Clinic Foundation  Cleveland Ohio United States of America"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9999-4003","authenticated-orcid":false,"given":"Adrian V.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"University of Connecticut\/Hartford Hospital Evidence\u2010based Practice Center  Hartford Connecticut United States of America"},{"name":"School of Medicine Universidad Peruana de Ciencias Aplicadas (UPC)  Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"HowladerN NooneAM KrapchoM et al.SEER Cancer Statistics Review 1975\u20102013 National Cancer Institute. Bethesda MD.https:\/\/seer.cancer.gov\/archive\/csr\/1975_2013\/"},{"key":"e_1_2_8_3_1","unstructured":"NooneAM HowladerN KrapchoM et al.Cancer Statistics Review 1975\u20102015 SEER Statistic. National Cancer Institute. Bethesda MD.https:\/\/seer.cancer.gov\/csr\/1975_2015\/"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.4065\/80.8.1087"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"issue":"12","key":"e_1_2_8_6_1","first-page":"1883","article-title":"Indolent B\u2010cell non\u2010Hodgkin's lymphomas","volume":"11","author":"Seng JE","year":"1997","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"e_1_2_8_7_1","first-page":"26","article-title":"Treatment of aggressive non\u2010Hodgkin's lymphoma: a North American perspective","volume":"19","author":"Sehn LH","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0921"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn195"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3392"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.105.105"},{"issue":"2","key":"e_1_2_8_12_1","first-page":"103","article-title":"Long\u2010term toxicity of chemotherapy and radiotherapy in lymphoma survivors: optimizing treatment for individual patients","volume":"13","author":"Hodgson DC","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/157340311799960645"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1242"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.4211"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-91-5-710"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12124"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.08.033"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.04.018"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624288"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2692.2692"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.936013"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281409"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.054"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji067"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.045"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0086"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20150409"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034405"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2016.6103"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.49.5.482"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.205"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archoto.2011.236"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30470"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.128413"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.6.368"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009567"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2607","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2607","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2607","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:08:44Z","timestamp":1694045324000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1002\/hon.2607"],"URL":"https:\/\/doi.org\/10.1002\/hon.2607","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"assertion":[{"value":"2018-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}